Download PDF
Thromb Haemost 1996; 76(04): 529-534
DOI: 10.1055/s-0038-1650617
Original Article
Schattauer GmbH Stuttgart

A Multicenter Randomized Double-blind Study of Enoxaparin Compared with Unfractionated Heparin in the Prevention of Venous Thromboembolic Disease in Elderly In-patients Bedridden for an Acute Medical Illness

Jean-Fraçois Bergmann
The Enoxaparin in Medicine Study Group
,
Eric Neuhart
The Enoxaparin in Medicine Study Group
› Author Affiliations
Further Information

Publication History

Received 08 November 1995

Accepted after resubmission 12 June 1996

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A multicenter, randomized double-blind study compared in two parallel groups the efficacy and safety of a low molecular weight heparin (LMWH) enoxaparin 20 mg once daily, with unfractionated heparin (UFH) 5000 IU twice daily, administered subcutaneously for 10 days, in the prevention of venous thrombosis disease in 442 hospitalized elderly patients bedridden for an acute medical illness. The main efficacy endpoint was defined as the occurrence of venous thrombosis, diagnosed by a daily fibrinogen uptake test, and/or documented clinical pulmonary embolism.

Intention-to-treat analysis of efficacy showed that the incidence of venous thromboembolic events was low: 4.8% (10/207) in the LMWH group (9 episodes of isotopic venous thrombosis and one of scintigraphic pulmonary embolism), and 4.6% (10/216) in the UFH group (10 episodes of isotopic venous thrombosis). The two treatments were equivalent, where equivalence was defined as a maximum difference of 7% between the two groups (p = 0.0005).

There were no significant differences in terms of safety between the 216 patients in the LMWH group and the 223 patients in the UFH group who received at least one injection of the randomized treatment. During the study period, 15 patients (3.4%) died (7 in the LMWH group and 8 in the UFH group): 2 sudden deaths, one in each group, including one case in which pulmonary embolism could not be excluded since no autopsy was performed, and 13 others deaths unrelated to the study treatments. Six patients (1.4%) presented a bleeding complication: 2 (0.9%) in the enoxaparin group (one major and one minor hemorrhage), and 4 (1.8%) in the UFH group (2 major and 2 minor hemorrhages).

These results indicate that subcutaneous enoxaparin 20 mg once daily for 10 days is as effective and well tolerated as subcutaneous UFH 5000 IU twice daily in the prevention of venous thromboembolic disease in bedridden elderly in-patients presenting an acute medical illness.

 

  • References

  • 1 Planes A, Vochelle N, Mazas F, Zuckman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60 (03) 407-410
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Barsotti J, Gruel Y, Rosset P, Favard L, Dabo B, Andreu J, Delahousse B, Leroy J. Comparative double blind study of two dosage regimens of low molecular weight heparin in elderly patients with femoral neck fracture. J Orthop Trauma 1990; 4 (04) 371-375
    CrossrefPubMedGoogle Scholar
  • 3 Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988; 75 (02) 128-131
    CrossrefPubMedGoogle Scholar
  • 4 Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920
    CrossrefPubMedGoogle Scholar
  • 5 Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briët E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156
    CrossrefPubMedGoogle Scholar
  • 6 Bergmann JF, Segrestaa JM, Caulin C. Prophylaxis against venous thromboembolism. Br Med J 1992; 305: 1156
    PubMedGoogle Scholar
  • 7 Clagett GP, Anderson FA, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism Chest 1995; (Suppl. 04) 108: 312-334
    CrossrefPubMed
  • 8 Gross JS, Neufeld RR, Libow LS, Gerber I, Rodstein M. Autopsy study of the elderly institutionalized patient. Review of 234 autopsies. Arch Intern Med 1988; 148: 173-176
    PubMedGoogle Scholar
  • 9 Lindblad B, Stemby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302: 709-711
    CrossrefPubMedGoogle Scholar
  • 10 Kierkegaard A, Norgren L, Olsson CG, Castenfors J, Persson G, Persson S. Incidence of deep vein thrombosis in bedridden non surgical patients. Acta Med Scand 1987; 222: 409-414
    PubMedGoogle Scholar
  • 11 Prescott RJ, Jones DRB, Vasilescu C, Henderson JT, Ruckley CV. Smoking and risk factors in deep vein thrombosis. Thromb Haemost 1978; 40: 128-133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Belch JJ, Lowe GDO, Ward AG, Prentice F, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-117
    CrossrefPubMedGoogle Scholar
  • 13 Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10 (07) 448-450
    CrossrefPubMedGoogle Scholar
  • 14 Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler J, Segrestaa JM. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159-164
    PubMedGoogle Scholar
  • 15 Sandercock PAG, Van Den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25
    CrossrefPubMedGoogle Scholar
  • 16 Prins MH, Gelsema R, van Heerde LR, den Ottolander GJH. Prophylaxis of deep venous thrombosis with a low molecular weight heparin (Kabi 2165) in stroke patients. Haemostasis 1989; 19: 245-250
    PubMedGoogle Scholar
  • 17 Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990; 16 (suppl) 25-33
    PubMedGoogle Scholar
  • 18 Turpie AGG, Hirsh J, Jay RM, Andrew M, Hull RD, Levine MN, Carter CJ, Powers PJ, Magnani HN, Gent M. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; 1: 523-526
    PubMedGoogle Scholar
  • 19 Anderson FA, Wheeler B, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660-1664
    CrossrefPubMedGoogle Scholar
  • 20 Coon WW. Epidemiology of venous thromboembolism. Ann Surg 1977; 186 (02) 149-164
    CrossrefPubMedGoogle Scholar
  • 21 Hirsh J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986; 8: 104B-113B
    CrossrefPubMedGoogle Scholar
  • 22 Janssen HF, Schachner J, Hubbard J, Hartman JT. The risk of deep venous thrombosis: A computerized epidemiologic approach. Surg 1987; 101 (02) 205-212
    PubMedGoogle Scholar
  • 23 Samama MM, Simonneau G, Wainstein JP, de Vathaire F, Huet Y, Landauer D. SIRIUS study: Epidemiology of risk factors of deep venous thrombosis of the lower limbs in community practice. Thromb Haemost 1993; 69 (06) 763 (Abs 797)
    PubMedGoogle Scholar
  • 24 Gibbs NM. Venous thrombosis of the lower limbs with particular reference to bedrest. Br J Surg 1957; 45: 209
    CrossrefPubMedGoogle Scholar
  • 25 Salzman EW, Hirsh J. Prevention of venous thromboembolism In: Hemostasis and thrombosis: Basic principles and clinical practice. Colman RW, Hirsh J, Marder V, Salzman EW. eds. JB Lippincott Compagny; Philadelphia, PA: 1987: 1252-1265
  • 26 Thromboembolic Risk Factors Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567-574
    PubMedGoogle Scholar
  • 27 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
    PubMedGoogle Scholar
  • 28 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M, Gent M, Kelton JG. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J 1995; 332: 1330-1335
    CrossrefPubMedGoogle Scholar
  • 29 Nicolaides AN. Prevention of venous thromboembolism - European consensus statement. International Angiol 1992; 11 (02) 151-159
    PubMedGoogle Scholar
  • 30 Anderson FA, Brownell WheelerM, Godberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-595
    CrossrefPubMedGoogle Scholar
  • 31 Anderson FA, Brownell WheelerM, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-938
    PubMedGoogle Scholar
  • 32 Halkin G, Golberg HJ, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 5
    PubMedGoogle Scholar
  • 33 Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49 (03) 388-410
    CrossrefPubMedGoogle Scholar
  • 34 Kakkar VV. Diagnosis of deep vein thrombosis using 125I fibrinogen test. Arch Surg 1972; 104: 152-159
    CrossrefPubMedGoogle Scholar
  • 35 Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information J 1991; 25: 411-424
    CrossrefPubMedGoogle Scholar
  • 36 Com-Noughe C, Rodary C. Revue des procedures statistiques pour mettre en évidence L’équivalence de deux traitements. Rev Epidemiol Sante Publ 1987; 35: 416-430
    PubMedGoogle Scholar
  • 37 Deheuvels P. How to analyze bioequivalence studies?. The right use of confidence intervals. J Organizational Behav Statist 1984; 1: 1-15
    PubMedGoogle Scholar
  • 38 Caulin C. Influence de I’administration de CY 216 sur la mortalité hospitaliere des patients alites en medecine interne. Etude coopérative internationale en double-insu, methodes et résultats préliminaries. In: Fraxiparine. Premier symposium international. Donnees analytiques, structurales, pharmacologiques et cliniques Breddin K, Fareed J, Samama M. eds. Stuttgart; New York: Schattauer: 1989: 149-154
  • 39 Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kiibler W, Heene DL. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990; 59: 639-650
    CrossrefPubMedGoogle Scholar
  • 40 Harenberg J, Roebruck P, Heinrich F, Schmitz-Huebner U, Heene DL. A randomized double blind trial of low molecular weight heparin for prophylaxis of thromboembolism in medical in-patients. Thromb Haemost 1993; 69 (06) 648 (AB 380)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Keller F, Flosbach CW. the PRIME study group. A randomized multicentre study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilized medical patients. Thromb Haemost 1995; 73 (06) 1106 (Abs 788)
    PubMedGoogle Scholar
  • 42 Wheeler HB, Hirsh J, Wells P, Anderson FA. Diagnosis tests for deep vein thrombosis Arch Intern Med 1994; 154: 1921-1928
    CrossrefPubMed
  • 43 Heijboer H, ten Cate JW, Btiller HR. Diagnosis of venous thrombosis. Semin Thromb Hemost 1991; 17 (Suppl. 03) 259-268
    PubMedGoogle Scholar